File downloaded on 2026-11-21
Source URL: https://medicines.health.europa.eu/veterinary/en/600000033973

Dexacortone 2 mg tablets for dogs and cats

Authorised

- Dexamethasone

Product identification

Medicine name:
Dexacortone 2 mg tablets for dogs and cats

Active substance:
Dexamethasone

Target species:
Dog
Cat

Route of administration:
Oral use

Product details

Active substance and strength:
Dexamethasone
2.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QH02AB02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Germany

Available in:
Germany

Package description:
Aluminium - PVC-PE-PVDC blister. Cardboard box of 5 blisters of 10 tablets.
Aluminium - PVC-PE-PVDC blister. Cardboard box of 1 blister of 10 tablets.
Aluminium - PVC-PE-PVDC blister. Cardboard box of 10 blisters of 10 tablets.
Aluminium - PVC-PE-PVDC blister. Cardboard box of 6 blisters of 10 tablets.
Aluminium - PVC-PE-PVDC blister. Cardboard box of 4 blisters of 10 tablets.
Aluminium - PVC-PE-PVDC blister. Cardboard box of 3 blisters of 10 tablets.
Aluminium - PVC-PE-PVDC blister. Cardboard box of 2 blisters of 10 tablets.
Aluminium - PVC-PE-PVDC blister. Cardboard box of 8 blisters of 10 tablets.
Aluminium - PVC-PE-PVDC blister. Cardboard box of 9 blisters of 10 tablets.
Aluminium - PVC-PE-PVDC blister. Cardboard box of 7 blisters of 10 tablets.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Le Vet. Beheer B.V.

Marketing authorisation date:

12/01/2018

Manufacturing sites for batch release:
Lelypharma B.V.
Genera d.d.

Responsible authority:
Federal Office Of Consumer Protection And Food Safety

Authorisation number:
402409.00.00

Date of authorisation status change:
12/01/2018

Reference member state:
Netherlands

Procedure number:
NL/V/0219/002

Concerned member states:
Austria Belgium Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 7/01/2026
Updated on: 14/03/2026
Download